A multicenter open-label randomized phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.

[1]  G. Daniels,et al.  Dabrafenib vs dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer - results of a randomized, phase 2, open-label, multicenter trial. , 2022, Thyroid : official journal of the American Thyroid Association.

[2]  A. Drilon,et al.  Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma , 2022, European journal of endocrinology.

[3]  A. Drilon,et al.  Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. , 2020, The New England journal of medicine.

[4]  I. Judson,et al.  Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial , 2019, The Lancet. Oncology.

[5]  A. Ravaud,et al.  A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. , 2017, European journal of cancer.

[6]  J. Fagin,et al.  Biologic and Clinical Perspectives on Thyroid Cancer. , 2016, The New England journal of medicine.

[7]  C. Andresen,et al.  A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment , 2015, Cancer.

[8]  Sung-Bae Kim,et al.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.

[9]  R. Paschke,et al.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.

[10]  Thomas Krause,et al.  Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. , 2012, The Lancet. Oncology.

[11]  K. Owzar,et al.  Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[12]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[13]  B. Goh,et al.  Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. , 2010, The Lancet. Oncology.

[14]  M. A. Pierotti,et al.  Rearrangements of NTRK1 gene in papillary thyroid carcinoma , 2010, Molecular and Cellular Endocrinology.

[15]  K. D. Williams,et al.  Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results , 2008 .

[16]  K. D. Williams,et al.  Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. , 2007, Thyroid : official journal of the American Thyroid Association.

[17]  Radiology,et al.  Clinical Cancer esearch cer Therapy : Clinical se II Study of Daily Sunitinib in FDG-PET – Positive , ne-Refractory Differentiated Thyroid Cancer and astatic Medullary Carcinoma of the Thyroid R Functional Imaging Correlation , 2010 .